Company Description
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific.
The company operates through two segments: Proteomics and Genomics. It provides SomaScan platform that enables researchers to measure thousands of proteins simultaneously, providing deep insights into biological processes and disease mechanism; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system redefines high-throughput genomics by delivering exceptional efficiency, precision, and scalability for qPCR applications.
It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations.
It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022.
Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 1999 |
| IPO Date | Feb 10, 2011 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 818 |
| CEO | Michael Egholm |
Contact Details
Address: 2 Tower Place, Suite 2000 South San Francisco, California 94080 United States | |
| Phone | 650 266 6000 |
| Website | standardbio.com |
Stock Details
| Ticker Symbol | LAB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001162194 |
| CUSIP Number | 34385P108 |
| ISIN Number | US34385P1084 |
| Employer ID | 77-0513190 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Egholm Ph.D. | President, Chief Executive Officer and Director |
| Hanjoon Kim | Chief Financial Officer |
| Jonathan Mickelsen | Vice President and Chief Accounting Officer |
| Elizabeth R. Jensen | Chief Human Resources Officer |
| Sean Mackay | Chief Business Officer and Senior Vice President |
| Dr. Stephen A. Williams BS, MB, Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 11, 2025 | 10-K | Annual Report |
| Mar 4, 2025 | SCHEDULE 13D/A | Filing |
| Feb 26, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 8-K | Current Report |
| Dec 20, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 144 | Filing |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |